Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A40AEG0
Wed, 12.11.2025
Pentixapharm Holding AG
Pentixapharm Publishes 9-Month Figures for 2025
Loss of the reporting period €12,7 million (attributed to research and development activities, personnel and other operating expenses)
Revenue of the reported period €117 thousands
Balance sheet total as of September 30, 2025: €43 million
Adjusted Guidance for the fiscal year 2025: expected loss a [ … ]
Mon, 10.11.2025
Pentixapharm Holding AG
Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
Berlin, Germany, November 10, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, will publish its financial results for the third quarter and firs [ … ]
Thu, 23.10.2025
Pentixapharm Holding AG
Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
Company focuses resources on its most advanced clinical development programs while reducing early-stage research activities
Organizational adjustments include a workforce reduction of approximately 50 %, expected to lower operating costs and extend cash runway into Q1 [ … ]
Mon, 06.10.2025
Pentixapharm Holding AG
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism
First-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early [ … ]
Fri, 26.09.2025
Pentixapharm Holding AG
Achieves Key Milestone with CXCR4-based Radiotherapeutic
Favorable safety profile enables advancement of radiolabeled PentixaTher to fourth of five planned activity dose levels in investigator-initiated PENTILULA Phase 1/2 trial
Milestone marks important step for novel radiotherapeutic candidate in high unmet need indication with limited treatme [ … ]
Fri, 25.04.2025
Pentixapharm Holding AG
Berlin, Germany, April 25, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, will present new pre-clinical data on its novel antibody GT-008 at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago. The presentation highlights GT-008’s unique glyca [ … ]
Thu, 24.04.2025
Pentixapharm Holding AG
Berlin, Germany, April 24, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company, today announced the signing of a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTh [ … ]
Tue, 15.04.2025
Pentixapharm Holding AG
Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions:
The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements.
Based on current planning, the Company expects a net loss of ap [ … ]
Mon, 03.03.2025
Pentixapharm Holding AG
Berlin, Germany, March 3, 2025 - Several previously announced personnel changes in the governing bodies of the Pentixapharm Group have taken effect as of March 1, 2025. The Management Board of the parent company Pentixapharm Holding AG is now identical in composition to the Management Board of the wholly owned operational subsidiary Pentixapharm AG [ … ]
Thu, 13.02.2025
Pentixapharm Holding AG
Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm’s Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2025) in San Francisco, CA.
The presentation features a case study of a [ … ]
